New Scientist Magazine Selects ACT’s Induced Pluripotent Stem (iPS) Cell-Derived Human Platelet Program As One of ‘10 …

MARLBOROUGH, Mass.--(BUSINESS WIRE)--

Advanced Cell Technology, Inc. (ACT; OTCBB: ACTC or the Company), a leader in the field of regenerative medicine, today announced that its iPS cell-derived human platelet program has been named as one of the 10 Ideas That Will Shape The Year in the Christmas and New Year Special issue of the New Scientist, widely considered to be one of the most influential science and technology news magazines in the world.

The list includes innovations in different scientific areas such as health and medicine, climate change, technology and others. ACTs platelet program aims to provide a renewable, donorless source of blood platelets to people in need of platelet transfusions.

Human iPS cells are a game-changer in medicine, said Robert Lanza, M.D., chief scientific officer of ACT. They offer the possibility to generate a non-controversial, unlimited source of patient-specific stem cells without embryo destruction. Owing to their short storage time, there is a constant demand for this life-saving blood component. Since platelets dont contain any genetic material, they cannot form tumors, which makes them ideal for the first clinical trial involving the iPS cell technology. We hope to initiate the first clinical trial using these promising cells in 2013.

ACT plans to compare normal and iPS cell-derived platelets in eight healthy volunteers and analyze recovery and survival. Additionally, normal platelets will be compared to human embryonic stem cell-derived platelet cells.

We appreciate this recognition from the New Scientist, commended Gary Rabin, chairman and CEO. It speaks to the growing importance of the stem cell and regenerative medicine sector.

Link to Article in New Scientist: http://www.newscientist.com/article/mg21628965.400-2013-smart-guide-revolutionary-human-stem-cell-trial.html

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

Forward-Looking Statements

See the original post here:
New Scientist Magazine Selects ACT’s Induced Pluripotent Stem (iPS) Cell-Derived Human Platelet Program As One of ‘10 ...